Immutep Limited (IMMP) 股票分析

公司概述

Immutep Limited is a biotechnology entity focused on developing novel immunotherapies based on the Lymphocyte Activation Gene-3 (LAG-3) pathway for the treatment of cancer and autoimmune diseases within the Australian market. Operating within the healthcare sector specifically under the biotechnology industry, the company leverages its lead product candidate, eftilagimod alfa (IMP321), which functions as a soluble LAG-3lg fusion protein designed to modulate the immune control mechanism. As of the latest reporting period, the company holds a market capitalization of $47.34M and generated annual revenue of $7.92M, while its employee count is not disclosed in the provided data. These valuation and revenue figures indicate that Immutep is a mid-sized biotechnology firm with significant growth potential but limited operational scale compared to large-cap pharmaceutical peers, reflecting the early-stage nature of its clinical development pipeline.

财务健康

The company reported a trailing twelve-month revenue of $7.92M, yet recorded a net income of -$83,916,456 and an EBITDA of -$82,390,280, revealing a substantial gap between top-line sales and bottom-line profitability driven by heavy research and development expenditures. The free cash flow stands at -$35,678,096, which signifies that the company is currently burning cash to fund its operations and clinical trials rather than generating positive liquidity from core business activities. Analysis of the margin structure shows a gross margin of 0.0%, an operating margin of -763.7%, and a profit margin of 0.0%, indicating that the company is not yet achieving profitability on its sales or covering its operating costs effectively. In terms of capital structure, the company holds $99.13M in cash against $1.21M in debt, resulting in a debt-to-equity ratio of 1.22, which suggests a balance sheet that carries leverage despite possessing a significant cash reserve. The current ratio is 2.97, indicating a strong ability to meet short-term obligations with its available liquid assets. Furthermore, the return on equity is -61.8% and the return on assets is -32.1%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate losses rather than positive returns.

估值评估

Valuation metrics for Immutep present a complex picture with a trailing P/E ratio of N/A and a forward P/E of -1.46, implying that the market does not yet expect the company to achieve positive earnings in the immediate forward period. The price-to-book ratio is 6.93, which suggests the market is pricing the company at a significant premium relative to its book value, likely due to the perceived value of its intellectual property and pipeline potential. Alternative valuation measures such as a price-to-sales ratio of 5.97 and an EV/EBITDA of -4.56 provide additional context, indicating that the company is valued primarily on revenue multiples rather than earnings or cash flow generation. Regarding trading range, the 52-week high is $3.53 and the 52-week low is $0.32, meaning the stock trades at a level that fluctuates widely within this established band. The beta value of 2.32 indicates that the stock's price volatility is substantially higher than that of the broader market, reflecting the inherent risks associated with biotechnology development stages.

Growth & Income

Immutep Limited demonstrated a revenue growth year-over-year of 91.5%, whereas earnings growth is N/A due to the lack of positive historical earnings, suggesting that top-line expansion is occurring while profitability remains elusive. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning all generated cash and capital are reinvested into research, development, and operational scaling rather than distributed to shareholders. This growth-oriented profile prioritizes advancing the eftilagimod alfa pipeline and expanding clinical data over providing immediate income to investors. Overall, the company's financial trajectory is characterized by rapid revenue acceleration coupled with negative earnings and cash flows, typical of biotechnology firms in the late-stage discovery or clinical trial phases.